229 related articles for article (PubMed ID: 2711157)
21. Determinants of remission of Paget's disease of bone.
Patel S; Stone MD; Coupland C; Hosking DJ
J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
Adami S; Salvagno G; Guarrera G; Montesanti F; Garavelli S; Rosini S; Lo Cascio V
Calcif Tissue Int; 1986 Oct; 39(4):226-9. PubMed ID: 2947663
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Paget's disease of bone with single dose intravenous pamidronate.
Watts RA; Skingle SJ; Bhambhani MM; Pountain G; Crisp AJ
Ann Rheum Dis; 1993 Aug; 52(8):616-8. PubMed ID: 8215628
[TBL] [Abstract][Full Text] [Related]
24. Intravenously administered pamidronate in the treatment of Paget's disease of bone.
Tucci JR; Bontha S
Endocr Pract; 2001; 7(6):423-9. PubMed ID: 11747277
[TBL] [Abstract][Full Text] [Related]
25. Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate).
Fraser TR; Ibbertson HK; Holdaway IM; Rutland M; King A; Dodd G; Wattie DJ
Aust N Z J Med; 1984 Dec; 14(6):811-8. PubMed ID: 6442563
[TBL] [Abstract][Full Text] [Related]
26. Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone.
Heynen G; Delwaide P; Bijvoet OL; Franchimont P
Eur J Clin Invest; 1982 Feb; 12(1):29-35. PubMed ID: 6802650
[No Abstract] [Full Text] [Related]
27. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease.
Vega E; Gonzalez D; Ghiringhelli G; Mautalen C
J Bone Miner Res; 1987 Aug; 2(4):267-71. PubMed ID: 3455613
[TBL] [Abstract][Full Text] [Related]
28. Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient.
Drake S; Massie JD; Postlethwaite AE; Palmieri GM
Arch Intern Med; 1989 Feb; 149(2):401-3. PubMed ID: 2783843
[TBL] [Abstract][Full Text] [Related]
29. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
Adami S; Zamberlan N; Mian M; Dorizzi R; Rossini M; Braga B; Gatti D; Bertoldo F; Locascio V
Bone Miner; 1994 May; 25(2):75-82. PubMed ID: 8086853
[TBL] [Abstract][Full Text] [Related]
30. Paget's disease of bone: five regimens of pamidronate treatment.
Pepersack T; Karmali R; Gillet C; François D; Fuss M
Clin Rheumatol; 1994 Mar; 13(1):39-44. PubMed ID: 8187442
[TBL] [Abstract][Full Text] [Related]
31. High-dose pamidronate in the management of resistant Paget's disease.
Cundy T; Wattie D; King AR
Calcif Tissue Int; 1996 Jan; 58(1):6-8. PubMed ID: 8825232
[TBL] [Abstract][Full Text] [Related]
32. Bone scintigraphy following intravenous pamidronate for Paget's disease of bone.
Ryan PJ; Gibson T; Fogelman I
J Nucl Med; 1992 Sep; 33(9):1589-93. PubMed ID: 1517830
[TBL] [Abstract][Full Text] [Related]
33. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F
Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
[TBL] [Abstract][Full Text] [Related]
34. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
35. Intravenous aminopropylidene bisphosphonate in the treatment of severe polyostotic Paget's disease of bone.
Fritz P; Lioté F; Kuntz D
Semin Arthritis Rheum; 1994 Feb; 23(4):282. PubMed ID: 8009260
[No Abstract] [Full Text] [Related]
36. Aminohexane diphosphonate in the treatment of Paget's disease of bone.
Atkins RM; Yates AJ; Gray RE; Urwin GH; Hamdy NA; Beneton MN; Rosini S; Kanis JA
J Bone Miner Res; 1987 Aug; 2(4):273-9. PubMed ID: 3455614
[TBL] [Abstract][Full Text] [Related]
37. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate.
Montagnani A; Gonnelli S; Cepollaro C; Campagna MS; Franci MB; Pacini S; Gennari C
Bone; 2003 Jan; 32(1):15-9. PubMed ID: 12584031
[TBL] [Abstract][Full Text] [Related]
38. Symptomatic and scintigraphic improvement after intravenous pamidronate treatment of Paget's disease of bone in patients with normal serum alkaline phosphatase levels.
Ang G; Feiglin D; Moses AM
Endocr Pract; 2003; 9(4):280-3. PubMed ID: 14561571
[TBL] [Abstract][Full Text] [Related]
39. Diphosphonate treatment of Paget's disease.
Finerman GA; Gonick HC; Smith RK; Mayfield JM
Clin Orthop Relat Res; 1976 Oct; (120):115-24. PubMed ID: 975646
[TBL] [Abstract][Full Text] [Related]
40. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile.
Vega E; Mautalen C; Roldán EJ; Pérez Lloret A
Drugs Exp Clin Res; 1994; 20(3):103-8. PubMed ID: 7956716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
